Therefore, identifying valuable and reliable biomarkers for predicting patient prognosis and anti-PD-1 immunotherapy response is crucial as it can benefit the diagnosis and treatment of NSCLC patients. Here, PDCD1 is linked to non-small cell lung carcinoma.